[go: up one dir, main page]

DK0781329T3 - Overekspression af mammale og virale proteiner - Google Patents

Overekspression af mammale og virale proteiner

Info

Publication number
DK0781329T3
DK0781329T3 DK95931798T DK95931798T DK0781329T3 DK 0781329 T3 DK0781329 T3 DK 0781329T3 DK 95931798 T DK95931798 T DK 95931798T DK 95931798 T DK95931798 T DK 95931798T DK 0781329 T3 DK0781329 T3 DK 0781329T3
Authority
DK
Denmark
Prior art keywords
mammalian
overexpression
viral proteins
gene encoding
protein
Prior art date
Application number
DK95931798T
Other languages
English (en)
Other versions
DK0781329T4 (da
Inventor
Brian Seed
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23262728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0781329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of DK0781329T3 publication Critical patent/DK0781329T3/da
Application granted granted Critical
Publication of DK0781329T4 publication Critical patent/DK0781329T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK95931798.3T 1994-09-19 1995-09-08 Overekspression af pattedyr- og virale proteiner DK0781329T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08324243 US5786464C1 (en) 1994-09-19 1994-09-19 Overexpression of mammalian and viral proteins
PCT/US1995/011511 WO1996009378A1 (en) 1994-09-19 1995-09-08 Overexpression of mammalian and viral proteins

Publications (2)

Publication Number Publication Date
DK0781329T3 true DK0781329T3 (da) 2006-12-11
DK0781329T4 DK0781329T4 (da) 2011-01-24

Family

ID=23262728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95931798.3T DK0781329T4 (da) 1994-09-19 1995-09-08 Overekspression af pattedyr- og virale proteiner

Country Status (13)

Country Link
US (1) US5786464C1 (da)
EP (1) EP0781329B2 (da)
JP (1) JPH10506278A (da)
AT (1) ATE335078T1 (da)
AU (1) AU3509995A (da)
CA (1) CA2200342C (da)
DE (1) DE69535147T3 (da)
DK (1) DK0781329T4 (da)
ES (1) ES2270430T5 (da)
PT (1) PT781329E (da)
TR (1) TR199501134A2 (da)
WO (1) WO1996009378A1 (da)
ZA (1) ZA957846B (da)

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
US20050074752A1 (en) * 1996-06-11 2005-04-07 Merck & Co., Inc. Synthetic hepatitis C genes
JP2002500502A (ja) 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
IL131131A0 (en) * 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
AU747522B2 (en) * 1997-07-09 2002-05-16 University Of Queensland, The Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6489141B1 (en) 1997-07-09 2002-12-03 The University Of Queensland Nucleic acid sequence and methods for selectively expressing a protein in a target cell or tissue
EP1002091B1 (en) * 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6602677B1 (en) * 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US20090148906A1 (en) * 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
EP1148885A4 (en) * 1999-02-08 2002-05-08 Chiron Corp ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES
EP1165798A2 (en) 1999-03-29 2002-01-02 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US7270984B1 (en) * 1999-06-25 2007-09-18 Basf Aktiengesellschaft Polynucleotides encoding a 6-phosphogluconolactonase polypeptide from corynebacterium glutamicum
WO2002064799A2 (en) * 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US20040063653A1 (en) * 2000-12-21 2004-04-01 Shiver John W. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US6502774B1 (en) * 2000-03-08 2003-01-07 J + L Fiber Services, Inc. Refiner disk sensor and sensor refiner disk
WO2001068835A2 (en) * 2000-03-13 2001-09-20 Aptagen Method for modifying a nucleic acid
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US20050209447A1 (en) * 2000-07-25 2005-09-22 Takashi Ito Process for producing recombinant protein
US7879540B1 (en) * 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US20030157643A1 (en) * 2000-08-24 2003-08-21 Almond Brian D Synthetic nucleic acids from aquatic species
WO2002042326A1 (en) * 2000-11-22 2002-05-30 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
CA2457959C (en) * 2001-06-05 2014-10-28 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
US6780974B2 (en) * 2001-06-12 2004-08-24 Cellomics, Inc. Synthetic DNA encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
CA2461056A1 (en) * 2001-09-20 2003-03-27 Glaxo Group Limited Hiv-gag codon-optimised dna vaccines
EP1501863A4 (en) 2002-05-03 2007-01-24 Sequenom Inc KINASE ANCHOR PROTEIN, PEPTIDES AND RELATED METHODS THEREOF
US7413874B2 (en) * 2002-12-09 2008-08-19 University Of Miami Nucleic acid encoding fluorescent proteins from aquatic species
US20050124017A1 (en) * 2003-12-05 2005-06-09 Stewart Lebrun Quantitative alkaline-phosphatase precipitation reagent and methods for visualization of protein microarrays
WO2005118874A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
DK1766002T3 (da) 2004-06-21 2015-12-07 Novozymes As Stabil opretholdelse af flere kopier af i det mindste to ORF i den samme orientering
US7728118B2 (en) 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
EP1934246B8 (en) 2005-10-07 2012-02-08 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Matrix metalloproteinase 11 vaccine
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
EP2082044B1 (en) * 2006-10-24 2016-06-01 Basf Se Method of increasing gene expression using modified codon usage
US20080248511A1 (en) * 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2662030T3 (es) * 2007-10-15 2018-04-05 Admedus Vaccines Pty Limited Sistema de construcciones y usos para el mismo
EP2385065A1 (en) 2007-11-01 2011-11-09 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US8126653B2 (en) * 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP2665818B1 (en) 2011-01-17 2017-03-22 Philip Morris Products S.a.s. Protein expression in plants
CN103502455A (zh) 2011-01-17 2014-01-08 菲利普莫里斯生产公司 用于在植物中核酸表达的载体
WO2013049227A2 (en) 2011-09-26 2013-04-04 Geneart Ag High efficiency, small volume nucleic acid synthesis
DK2771031T3 (da) 2011-10-28 2018-05-28 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
CN104619724B (zh) 2012-01-27 2018-05-04 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2867950C (en) 2012-03-22 2023-02-21 Crucell Holland B.V. Vaccine against rsv
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
ES2760023T3 (es) 2013-02-20 2020-05-12 Univ Pennsylvania Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
US10563240B2 (en) 2013-03-14 2020-02-18 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
SMT201900138T1 (it) 2013-04-25 2019-05-10 Janssen Vaccines & Prevention Bv Polipeptidi f di rsv pre-fusione solubili stabilizzati
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
CA3225456A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US20170158755A1 (en) 2014-03-12 2017-06-08 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
KR20240042250A (ko) 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
MX379069B (es) 2014-11-04 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP6951973B2 (ja) 2014-11-12 2021-10-20 シージェン インコーポレイテッド グリカン相互作用化合物及び使用方法
CN107532129B (zh) 2014-12-09 2022-09-13 生命技术公司 高效小体积核酸合成
RU2021118125A (ru) 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
PT4108769T (pt) 2015-05-29 2023-10-10 Curevac Mfg Gmbh Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
MY195389A (en) 2015-08-20 2023-01-18 Janssen Vaccines & Prevention Bv Therapeutic HPV18 Vaccines
AU2016316723B2 (en) 2015-09-02 2021-03-25 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2016353153B2 (en) 2015-11-12 2023-11-23 Seagen Inc. Glycan-interacting compounds and methods of use
LT3380620T (lt) 2015-11-23 2024-09-10 Novartis Ag Optimizuoti lentivirusiniai pernešimo vektoriai ir jų panaudojimas
SG11201805449PA (en) 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
EP4219689A3 (en) 2015-12-30 2023-12-20 Novartis AG Immune effector cell therapies with enhanced efficacy
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EA201891909A1 (ru) 2016-03-11 2019-02-28 Сколар Рок, Инк. TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
JP7497955B6 (ja) 2016-04-15 2024-07-01 ノバルティス アーゲー 選択的タンパク質発現のための組成物および方法
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
SG11201808809PA (en) 2016-05-02 2018-11-29 Janssen Vaccine & Prevention B V Therapeutic hpv vaccine combinations
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
BR112018074483A2 (pt) 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
TWI797091B (zh) 2016-10-07 2023-04-01 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
WO2018087285A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 antigen binding proteins and uses thereof
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110573523A (zh) 2017-02-28 2019-12-13 宾夕法尼亚州大学信托人 基于aav载体的流感疫苗
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
LT3589730T (lt) 2017-02-28 2024-03-12 The Trustees Of The University Of Pennsylvania Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR102551733B1 (ko) 2017-05-22 2023-07-06 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
AU2017434556B2 (en) 2017-09-28 2024-11-14 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
BR112020007710A2 (pt) 2017-10-25 2020-10-20 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
AU2018375163A1 (en) 2017-11-30 2020-06-11 The Trustees Of The University Of Pennsylvania Gene therapy for mucopolysaccharidosis IIIB
CA3083416A1 (en) 2017-11-30 2019-06-06 The Trustees Of The University Of Pennsylvania Gene therapy for mucopolysaccharidosis iii a
WO2019118518A2 (en) 2017-12-11 2019-06-20 Senti Biosciences, Inc. Inducible cell receptors for cell-based therapeutics
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
MX2020007777A (es) 2018-01-23 2020-09-18 Janssen Vaccines & Prevention Bv Vacunas contra virus de la gripe y usos de las mismas.
EP3768858A1 (en) 2018-03-19 2021-01-27 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202013231SA (en) 2018-07-11 2021-01-28 Scholar Rock Inc HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
WO2020047452A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
BR112021007765A2 (pt) 2018-10-23 2021-08-03 Scholar Rock, Inc. inibidores seletivos de rgmc e uso dos mesmos
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CA3117816A1 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
JP2022517324A (ja) 2019-01-03 2022-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌を患っている被験者における、ｃｄ８陽性ｔ細胞依存性免疫応答を増強させるための方法及び医薬組成物
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CA3137448A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
EP3769816A1 (en) 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
CN114430742A (zh) 2019-09-05 2022-05-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
KR20220116522A (ko) 2019-12-20 2022-08-23 노파르티스 아게 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4087649A1 (en) 2020-01-11 2022-11-16 Scholar Rock, Inc. Tgfbeta inhibitors and use thereof
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2021229448A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Rna replicon encoding a stabilized corona virus spike protein
PH12022552935A1 (en) 2020-05-11 2024-02-12 Janssen Pharmaceuticals Inc Stabilized coronavirus spike protein fusion proteins
JP2023531451A (ja) 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
MX2023000373A (es) 2020-07-06 2023-02-13 Janssen Pharmaceuticals Inc Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
WO2022008027A1 (en) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
US20230323299A1 (en) 2020-08-03 2023-10-12 Inserm (Institut National De La Santé Et De La Recherch Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
JP2023545433A (ja) 2020-10-09 2023-10-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ファブリー病の治療のための組成物及び方法
EP3992205A1 (en) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Sars coronavirus-2 spike protein binding compounds
JP2023547507A (ja) 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
JP2023549504A (ja) 2020-11-13 2023-11-27 ノバルティス アーゲー キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
CA3211197A1 (en) 2021-02-23 2022-09-01 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
EP4301402A1 (en) 2021-03-03 2024-01-10 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Bispecific antibodies enhancing cell mediated immune responses
EP4313317A1 (en) 2021-03-23 2024-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of t cell-lymphomas
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022207839A2 (en) 2021-04-01 2022-10-06 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20240382592A1 (en) 2021-04-09 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of anaplastic large cell lymphoma
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20240408157A1 (en) 2021-12-02 2024-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
EP4479143A1 (en) 2022-02-18 2024-12-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023196892A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
EP4504797A1 (en) 2022-04-06 2025-02-12 The Trustees of The University of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
IL316911A (en) 2022-05-12 2025-01-01 Msd Int Business Gmbh Stabilized HMPV prefusion proteins
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024018003A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
WO2024052318A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
TW202423983A (zh) 2022-09-15 2024-06-16 瑞士商諾華公司 使用嵌合抗原受體療法的自體免疫性障礙的治療
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024084082A1 (en) 2022-10-21 2024-04-25 Meatable B.V. Adipocyte maturation
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024133940A2 (en) 2022-12-23 2024-06-27 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024151213A2 (en) 2023-01-12 2024-07-18 National University Of Singapore Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies
WO2024170702A1 (en) 2023-02-15 2024-08-22 Meatable B.V. Maturation of skeletal muscle cells
WO2024170696A1 (en) 2023-02-15 2024-08-22 Meatable B.V. Maturation of skeletal muscle cells
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2024209036A1 (en) 2023-04-07 2024-10-10 Institut National de la Santé et de la Recherche Médicale Generating highly pure glutamatergic neuronal populations using the pro-neural factor ascl1
WO2024209270A2 (en) 2023-04-07 2024-10-10 Infinitopes Limited Methods and compositions for cancer treatment using recombinant polypeptides
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
US20240360431A1 (en) 2023-04-30 2024-10-31 Sichuan Real&Best Biotech Co., Ltd. Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
WO2024252001A1 (en) 2023-06-08 2024-12-12 Meatable B.V. Methods for culturing cells
WO2024258961A1 (en) 2023-06-12 2024-12-19 The Trustees Of The University Of Pennsylvania Aav gene therapy for mucopolysaccharidosis iiib
WO2025017186A1 (en) 2023-07-20 2025-01-23 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with a tethering system for cargo delivery
WO2025035143A1 (en) 2023-08-10 2025-02-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
WO2025048716A1 (en) 2023-08-25 2025-03-06 Axcynsis Therapeutics Pte. Ltd. Anti-alpp/alppl2 antibodies, antibody-drug conjugates, and uses thereof
WO2025059491A2 (en) 2023-09-15 2025-03-20 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
WO2025059515A2 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Cell penetrating agents and uses thereof
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US5464774A (en) * 1984-03-05 1995-11-07 The Salk Institute For Biological Studies Bovine basic fibroblast growth factor
US5276268A (en) * 1986-08-23 1994-01-04 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5244797B1 (en) * 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins

Also Published As

Publication number Publication date
US5786464C1 (en) 2012-04-24
CA2200342A1 (en) 1996-03-28
JPH10506278A (ja) 1998-06-23
WO1996009378A1 (en) 1996-03-28
EP0781329B2 (en) 2010-12-29
EP0781329B1 (en) 2006-08-02
ES2270430T5 (es) 2011-05-12
CA2200342C (en) 2009-03-03
DE69535147D1 (de) 2006-09-14
DE69535147T2 (de) 2007-07-05
ATE335078T1 (de) 2006-08-15
EP0781329A1 (en) 1997-07-02
ES2270430T3 (es) 2007-04-01
AU3509995A (en) 1996-04-09
ZA957846B (en) 1997-03-18
DK0781329T4 (da) 2011-01-24
US5786464A (en) 1998-07-28
TR199501134A2 (tr) 1996-06-21
PT781329E (pt) 2006-12-29
DE69535147T3 (de) 2011-07-07
EP0781329A4 (en) 1998-11-25

Similar Documents

Publication Publication Date Title
DK0781329T3 (da) Overekspression af mammale og virale proteiner
DK0929564T3 (da) Höjniveau-ekspression af proteiner
DK0851868T3 (da) Höjniveau-ekspression af proteiner
DK1090129T4 (da) Overekspression af phytase-gener i gærsystemer
NZ503850A (en) April - a novel protein with growth effects
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
GB9307371D0 (en) Fusion proteins
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
DK0546087T3 (da) Proteinstruktur af plantetoksinet gelonin
DE3582136D1 (de) Gen fuer ein protein mit insektizider wirkung.
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69534738D1 (de) Leukocyten-aktivierender Faktor
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
DE69415548D1 (de) Haemoregulatorische penta-oder hexapeptide
SE9302856D0 (sv) Method and means for producing a plasmapeotein-binding protein